{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:17:26Z","timestamp":1791087446451,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.medmal.2007.02.009","type":"journal-article","created":{"date-parts":[[2007,7,31]],"date-time":"2007-07-31T15:11:58Z","timestamp":1185894718000},"page":"617-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Le traitement de\u00a0la\u00a0tuberculose en\u00a02007"],"prefix":"10.1016","volume":"37","author":[{"given":"P.","family":"Tattevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2007.02.009_bib1","unstructured":"WHO. Global tuberculosis control: Surveillance, planning, financing. WHO report. http:\/\/www.who.int\/tb\/publications\/global_report\/2006\/download_centre\/en\/index.html. Geneva: World Health Organization, 2006."},{"key":"10.1016\/j.medmal.2007.02.009_bib2","unstructured":"Onusida. Le point sur l\u2019\u00e9pid\u00e9mie de sida http:\/\/www.unaids.org\/en\/HIV_data\/epi2006\/default.asp, 2006."},{"key":"10.1016\/j.medmal.2007.02.009_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/14787210.1.3.483","article-title":"A review of tuberculosis: reflections on the past, present and future of a global epidemic disease","volume":"1","author":"Smith","year":"2003","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.medmal.2007.02.009_bib4","first-page":"1412","article-title":"An outbreak of drug-resistant tuberculosis caused by a Beijing strain in the western Cape, South Africa","volume":"10","author":"Johnson","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib5","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.2174\/138161206778743646","article-title":"Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities","volume":"12","author":"Tomioka","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.medmal.2007.02.009_bib6","first-page":"954","article-title":"In the European Union, TB patients from former Soviet countries have a high risk of multidrug resistance","volume":"10","author":"Falzon","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.1994.03510330043032","article-title":"Nationwide survey of drug-resistant tuberculosis in the United States","volume":"271","author":"Bloch","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.medmal.2007.02.009_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkl298","article-title":"Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis","volume":"58","author":"Park","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2007.02.009_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jac\/dki148","article-title":"Linezolid for the treatment of multidrug-resistant tuberculosis","volume":"56","author":"Fortun","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2007.02.009_bib10","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1128\/AAC.47.10.3117-3122.2003","article-title":"Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo","volume":"47","author":"Veziris","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2007.02.009_bib11","unstructured":"WHO. Anti-TB drug resistance in the world. http:\/\/www.who.int\/tb\/publications\/who_htm_tb_2004_343\/en\/index.html. 2005."},{"key":"10.1016\/j.medmal.2007.02.009_bib12","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1086\/344657","article-title":"Tuberculosis drug resistance: a global threat","volume":"36","author":"Nachega","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib13","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1056\/NEJM200104263441706","article-title":"Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance","volume":"344","author":"Espinal","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib14","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1001\/jama.293.22.2788","article-title":"Multidrug-resistant tuberculosis: news from the front","volume":"293","author":"Nettleman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.medmal.2007.02.009_bib15","first-page":"430","article-title":"Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control","volume":"81","year":"2006","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.medmal.2007.02.009_bib16","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(06)69573-1","article-title":"Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa","volume":"368","author":"Gandhi","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2007.02.009_bib17","first-page":"301","article-title":"Emergence of Mycobacterium\u00a0tuberculosis with extensive resistance to second-line drugs--worldwide, 2000\u20132004","volume":"55","year":"2006","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.medmal.2007.02.009_bib18","first-page":"121","article-title":"Les cas de tuberculose d\u00e9clar\u00e9s en France en 2004","volume":"18","author":"Che","year":"2006","journal-title":"Bull. Epidemiol. Hebd."},{"key":"10.1016\/j.medmal.2007.02.009_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1183\/09031936.03.00014103","article-title":"Multidrug-resistant tuberculosis: eight years of surveillance in France","volume":"22","author":"Robert","year":"2003","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.medmal.2007.02.009_bib20","first-page":"7S3","article-title":"Conseil sup\u00e9rieur d'hygi\u00e8ne publique de France. Pr\u00e9vention et prise en charge de la Tuberculose en France","volume":"20","year":"2003","journal-title":"Rev. Mal. Respir."},{"key":"10.1016\/j.medmal.2007.02.009_bib21","first-page":"1","article-title":"Centers for Disease Control and prevention. Treatment of tuberculosis, American Thoracic Society, CDC and Infectious Diseases Society of America","volume":"52","year":"2003","journal-title":"MMWR"},{"key":"10.1016\/j.medmal.2007.02.009_bib22","series-title":"Guidelines for the management of drug resistant tuberculosis","author":"Crofton","year":"1997"},{"key":"10.1016\/j.medmal.2007.02.009_bib23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/314007","article-title":"Practice guidelines for the treatment of tuberculosis","volume":"31","author":"Horsburgh","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib24","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/S0755-4982(06)74895-3","article-title":"Argumentation sur la dur\u00e9e des traitements antituberculeux","volume":"35","author":"Veziris","year":"2006","journal-title":"Presse Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1164\/ajrccm\/143.4_Pt_1.700","volume":"143","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib26","first-page":"165","article-title":"Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African\/British Medical Research Councils Study","volume":"123","year":"1981","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1378\/chest.115.5.1248","article-title":"The validity of medical history, classic symptoms, and chest radiographs in predicting pulmonary tuberculosis: derivation of a pulmonary tuberculosis prediction model","volume":"115","author":"Tattevin","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.medmal.2007.02.009_bib28","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/23.5.954","article-title":"How contagious is tuberculosis?","volume":"23","author":"Sepkowitz","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib29","first-page":"1751","article-title":"Management of tuberculosis in France: guidelines of the French Pulmonary Society","volume":"35","year":"2006","journal-title":"Presse Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/345532","article-title":"A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin","volume":"36","author":"Tattevin","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib31","unstructured":"Y\u00e9ni P. Rapport d'experts sur la prise en charge m\u00e9dicale des personnes infect\u00e9es par le VIH en 2006. http:\/\/www.sante.gouv.fr\/htm\/actu\/yeni_sida\/rapport_experts_2006.pdf. 2006."},{"key":"10.1016\/j.medmal.2007.02.009_bib32","first-page":"3883","article-title":"Management of tuberculosis in the United States","volume":"39","author":"Small","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib33","first-page":"1909","article-title":"Tuberculosis. Current therapeutics","volume":"25","author":"Tattevin","year":"1996","journal-title":"Presse Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/00003495-199243050-00003","article-title":"Drug treatment of tuberculosis-1992","volume":"43","author":"Davidson","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2007.02.009_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0041-3879(77)90022-8","article-title":"The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide","volume":"59","author":"Girling","year":"1978","journal-title":"Tubercle"},{"key":"10.1016\/j.medmal.2007.02.009_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.medmal.2007.02.009_bib37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1164\/arrd.1983.128.3.419","article-title":"Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis","volume":"128","author":"Dutt","year":"1983","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib38","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14740338.5.2.231","article-title":"Adverse reactions to first-line antituberculosis drugs","volume":"5","author":"Forget","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.medmal.2007.02.009_bib40","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/499244","article-title":"Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection","volume":"42","author":"Ijaz","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0041-3879(80)90007-0","article-title":"Interaction of rifampicin with other drugs","volume":"61","author":"Acocella","year":"1980","journal-title":"Tubercle"},{"key":"10.1016\/j.medmal.2007.02.009_bib42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/bmj.286.6369.923","article-title":"Rifampicin reduces effectiveness and bioavailability of prednisolone","volume":"286","author":"McAllister","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.medmal.2007.02.009_bib43","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJM199404283301702","article-title":"The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis","volume":"330","author":"Weis","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/0003-4819-76-3-112-6-407","article-title":"A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen","volume":"112","author":"Cohn","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/rccm.200603-360OC","article-title":"Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis","volume":"174","author":"Burman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib46","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1128\/AAC.50.4.1599-1602.2006","article-title":"Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients","volume":"50","author":"Bishop","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2007.02.009_bib47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/341309","article-title":"Linezolid-induced pancytopenia","volume":"35","author":"Halpern","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib48","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1164\/ajrccm.160.2.9901012","article-title":"Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study","volume":"160","author":"Flament-Saillour","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002030-200201040-00010","article-title":"Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy","volume":"16","author":"Dean","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2007.02.009_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s002640050311","volume":"23","year":"1999","journal-title":"Int. Orthop."},{"key":"10.1016\/j.medmal.2007.02.009_bib51","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1302\/0301-620X.80B3.0800456","article-title":"A 15-year assessment of controlled trials of the management of tuberculosis of the spine in Korea and Hong Kong. Thirteenth Report of the Medical Research Council Working Party on Tuberculosis of the Spine","volume":"80","year":"1998","journal-title":"J. Bone Joint Surg. Br."},{"key":"10.1016\/j.medmal.2007.02.009_bib52","series-title":"Tuberculose: une maladie toujours d'actualit\u00e9","first-page":"109","article-title":"Tuberculose: dans quelles situations peut-on discuter une corticoth\u00e9rapie?","author":"Tattevin","year":"2002"},{"key":"10.1016\/j.medmal.2007.02.009_bib53","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib54","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/515543","article-title":"Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature","volume":"25","author":"Dooley","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/165.1.1","article-title":"Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. Working Group on Steroid Use, Antimicrobial Agents Committee, Infectious Diseases Society of America","volume":"165","author":"McGowan","year":"1992","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib56","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200124070-00006","article-title":"Drug treatment for tuberculosis during pregnancy: safety considerations","volume":"24","author":"Bothamley","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.medmal.2007.02.009_bib57","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"Pai","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.medmal.2007.02.009_bib58","unstructured":"AFSSAPS. Recommandations nationales sur la pr\u00e9vention et la prise en charge des tuberculoses survenant sous anti-TNF alpha. Acc\u00e8s le 25 janvier 2007. http:\/\/www.agmed.sante.gouv.fr\/htm\/10\/tnf\/reco.pdf. Vol. 2007."},{"key":"10.1016\/j.medmal.2007.02.009_bib59","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejim.2006.02.021","article-title":"Tuberculosis treatment duration in France: From guidelines to daily practice","volume":"17","author":"Tattevin","year":"2006","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.medmal.2007.02.009_bib60","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1001\/jama.1995.03530210060032","article-title":"Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association","volume":"274","author":"Wilson","year":"1995","journal-title":"JAMA"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X07001515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X07001515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:02:37Z","timestamp":1759971757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X07001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0399077X07001515"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2007.02.009","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le traitement de\u00a0la\u00a0tuberculose en\u00a02007","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2007.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}